JP5090621B2 - Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法 - Google Patents

Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法 Download PDF

Info

Publication number: JP5090621B2
Authority: JP; Japan
Prior art keywords: inhibitors; disclosed; formula; sglt2; compound
Prior art date: 2002-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP2004507493A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005531588A (ja

Inventor

ブルース・エルズワース

ウィリアム・エヌ・ウォッシュバーン

フィリップ・エム・シャー

ガン・ウ

メン・ウェイ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-20

Filing date

2003-05-15

Publication date

2012-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29582046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5090621(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-15 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2005-10-20 Publication of JP2005531588A publication Critical patent/JP2005531588A/ja

2012-12-05 Application granted granted Critical

2012-12-05 Publication of JP5090621B2 publication Critical patent/JP5090621B2/ja

2023-05-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

0 *C*c1ccccc1 Chemical compound *C*c1ccccc1 0.000 description 4
XYECZFBHELFLOH-XALOWKIYSA-N CCOc1ccc(Cc2cc([C@@H]([C@@H](C34CC3)O)O[C@](C3)([C@@H]3O)[C@H]4O)ccc2Cl)cc1 Chemical compound CCOc1ccc(Cc2cc([C@@H]([C@@H](C34CC3)O)O[C@](C3)([C@@H]3O)[C@H]4O)ccc2Cl)cc1 XYECZFBHELFLOH-XALOWKIYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
- C07C45/46—Friedel-Crafts reactions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP2004507493A 2002-05-20 2003-05-15 Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法 Expired - Lifetime JP5090621B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/151,436		2002-05-20
US10/151,436 US6515117B2 (en)	1999-10-12	2002-05-20	C-aryl glucoside SGLT2 inhibitors and method
PCT/US2003/015591 WO2003099836A1 (fr)	2002-05-20	2003-05-15	C-aryl glucosides en tant qu'inhibiteurs de sglt-2 et methode correspondante

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2009189324A Division JP5340077B2 (ja)	2002-05-20	2009-08-18	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2012160579A Division JP5584738B2 (ja)	2002-05-20	2012-07-19	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法

Publications (2)

Publication Number	Publication Date
JP2005531588A JP2005531588A (ja)	2005-10-20
JP5090621B2 true JP5090621B2 (ja)	2012-12-05

Family

ID=29582046

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP2004507493A Expired - Lifetime JP5090621B2 (ja)	2002-05-20	2003-05-15	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2009189324A Expired - Lifetime JP5340077B2 (ja)	2002-05-20	2009-08-18	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2012160579A Expired - Lifetime JP5584738B2 (ja)	2002-05-20	2012-07-19	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2013161572A Expired - Lifetime JP5604568B2 (ja)	2002-05-20	2013-08-02	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
JP2009189324A Expired - Lifetime JP5340077B2 (ja)	2002-05-20	2009-08-18	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2012160579A Expired - Lifetime JP5584738B2 (ja)	2002-05-20	2012-07-19	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法
JP2013161572A Expired - Lifetime JP5604568B2 (ja)	2002-05-20	2013-08-02	Ｃ−アリールグルコシドｓｇｌｔ２インヒビターおよび方法

Country Status (39)

Country	Link
US (1)	US6515117B2 (fr)
EP (1)	EP1506211B1 (fr)
JP (4)	JP5090621B2 (fr)
KR (1)	KR101021752B1 (fr)
CN (5)	CN101092409A (fr)
AR (1)	AR040032A1 (fr)
AT (1)	ATE353334T1 (fr)
AU (1)	AU2003237886B2 (fr)
BE (2)	BE2013C025I2 (fr)
BR (2)	BR122017015091B8 (fr)
CA (1)	CA2486539C (fr)
CY (3)	CY1106465T1 (fr)
DE (1)	DE60311649T2 (fr)
DK (1)	DK1506211T3 (fr)
ES (1)	ES2280759T3 (fr)
FR (2)	FR13C0022I2 (fr)
GE (1)	GEP20084403B (fr)
HK (1)	HK1205120A1 (fr)
HR (1)	HRP20041084B1 (fr)
IL (1)	IL165119A0 (fr)
IN (1)	IN2004DE03573A (fr)
IS (1)	IS7529A (fr)
LT (1)	LTC1506211I2 (fr)
LU (2)	LU92182I2 (fr)
ME (2)	ME00091B (fr)
MX (1)	MX249731B (fr)
MY (1)	MY142499A (fr)
NO (4)	NO329107B1 (fr)
NZ (1)	NZ536605A (fr)
PE (1)	PE20040760A1 (fr)
PL (1)	PL210304B1 (fr)
PT (1)	PT1506211E (fr)
RS (1)	RS51469B (fr)
RU (4)	RU2337916C2 (fr)
SI (1)	SI1506211T1 (fr)
TW (1)	TWI310770B (fr)
UA (1)	UA77306C2 (fr)
WO (1)	WO2003099836A1 (fr)
ZA (1)	ZA200409295B (fr)

Families Citing this family (351)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh) *	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
FR2809310B1 (fr) *	2000-05-26	2004-02-13	Centre Nat Rech Scient	Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
US20020082222A1 (en)	2000-11-30	2002-06-27	Shapira Nathan Andrew	Treatments for neurogenetic disorders, impulse control disorder, and wound healing
KR100926247B1 (ko) *	2001-02-24	2009-11-12	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
WO2002080936A1 (fr) *	2001-04-04	2002-10-17	Ortho Mcneil Pharmaceutical, Inc.	Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
WO2002083066A2 (fr) *	2001-04-11	2002-10-24	Bristol-Myers Squibb Company	Complexes acides amines de glugocides c-aryle pour le traitement du diabete et procede correspondant
US20030087843A1 (en) *	2001-09-05	2003-05-08	Washburn William N.	O-pyrazole glucoside SGLT2 inhibitors and method of use
TWI254635B (en) *	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2500873C (fr) *	2002-10-04	2012-01-17	Kissei Pharmaceutical Co., Ltd.	Derive de pyrazole, composition medicinale renfermant ce derive, utilisation medicinale de cette composition, et intermediaire entrant dans sa production
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0317929A (pt) *	2003-01-03	2006-04-11	Bristol Myers Squibb Co	métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
EP1457206A1 (fr) *	2003-03-13	2004-09-15	Fournier Laboratories Ireland Limited	Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité
ES2567571T3 (es)	2003-03-14	2016-04-25	Astellas Pharma Inc.	Derivados de C-glucósido y sales de los mismos
JP2004300102A (ja) *	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
RS20060320A (sr) *	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
TW200524951A (en) *	2003-08-01	2005-08-01	Janssen Pharmaceutica Nv	Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
EA010422B1 (ru) *	2003-08-01	2008-08-29	Янссен Фармацевтика Н.В.	Замещённые индол-о-глюкозиды
EP1679965A4 (fr) *	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	C-glycosides heterocycliques fusionnes substitues
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
LT2896397T (lt) *	2003-08-01	2017-11-27	Mitsubishi Tanabe Pharma Corporation	Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
US7371759B2 (en) *	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en) *	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1724277A4 (fr) *	2004-03-04	2012-05-02	Kissei Pharmaceutical	Derive heterocyclique accole, composition medicamenteuse en contenant, et son utilisation medicamenteuse
ATE557013T1 (de) *	2004-03-16	2012-05-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ES2282062T1 (es)	2004-06-04	2007-10-16	Teva Pharmaceutical Industries Ltd.	Composicion farmaceutica que contiene irbesartan.
US7393836B2 (en) *	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004034690A1 (de) *	2004-07-17	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) *	2004-07-26	2006-02-16	Chugai Pharmaceutical Co Ltd	Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (fr) *	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
AR051446A1 (es) *	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US20080139484A1 (en) *	2004-09-29	2008-06-12	Kissei Pharmaceutical Co., Ltd.	1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof
DE102004048388A1 (de)	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2006044531A2 (fr) *	2004-10-13	2006-04-27	Isis Parmaceuticals, Inc.	Modulation antisens de l'expression de ptp1b
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587639A1 (fr) *	2004-12-16	2006-06-22	Boehringer Ingelheim International Gmbh	Derives de benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
TW200637869A (en) *	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI365186B (en) *	2005-01-31	2012-06-01	Mitsubishi Tanabe Pharma Corp	Indole derivatives
WO2006086464A2 (fr) *	2005-02-10	2006-08-17	Bristol-Myers Squibb Company	Dihydroquinazolinones utilisees comme modulateurs de la 5ht
ATE445608T1 (de) *	2005-02-23	2009-10-15	Boehringer Ingelheim Int	Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
ATE453656T1 (de) *	2005-04-15	2010-01-15	Boehringer Ingelheim Int	Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) *	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) *	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (fr) *	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
TW200726755A (en) *	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
ES2346347T3 (es) *	2005-07-27	2010-10-14	Boehringer Ingelheim International Gmbh	Derivados de ((hetero)cicloalquiletinil-bencil)-benceno y su uso como inhibidores del cotransportador de glucosa dependiente de sodio (sglt).
CA2617102A1 (fr) *	2005-07-28	2007-02-08	Bristol-Myers Squibb Company	Tetrahydro-1h-pyrido[4,3,b]indoles substitues utilises en tant qu'agonistes et antagonistes des recepteurs de la serotonine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7795436B2 (en) *	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
CA2620566A1 (fr) *	2005-08-30	2007-03-08	Boehringer Ingelheim International Gmbh	Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
TW200745075A (en) *	2005-09-08	2007-12-16	Boehringer Ingelheim Int	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) *	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
WO2007074884A1 (fr) *	2005-12-28	2007-07-05	Takeda Pharmaceutical Company Limited	Agent thérapeutique pour traiter le diabète
WO2007093610A1 (fr) *	2006-02-15	2007-08-23	Boehringer Ingelheim International Gmbh	Dérivés de benzonitrile substitués par glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leurs applications et un procédé pour leur fabrication
PE20080697A1 (es) *	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2007143052A1 (fr) *	2006-06-01	2007-12-13	Glycomimetics, Inc.	Galactosides et thiodigalactosides en tant qu'inhibiteurs de la lectine pa-il de pseudomonas
DE102006028862A1 (de)	2006-06-23	2007-12-27	Merck Patent Gmbh	3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) *	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en)	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI432446B (zh)	2006-07-27	2014-04-01	Chugai Pharmaceutical Co Ltd	稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh) *	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
TWI403516B (zh)	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
CA2656847A1 (fr)	2006-08-15	2008-02-21	Boehringer Ingelheim International Gmbh	Derives de cyclopropyl-benzene a substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composes, leur utilisation en tant qu'inhibiteurs de sglt et leur procede de fabrication
US8945582B2 (en) *	2006-09-07	2015-02-03	Glaxosmithkline Biologicals S.A.	Vaccine
TWI499414B (zh)	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
US20080194575A1 (en) *	2006-10-04	2008-08-14	Naiara Beraza	Treatment for non-alcoholic-steatohepatitis
US20100093744A1 (en) *	2006-10-13	2010-04-15	Chugai Seiyaku Kabushiki Kaisha	Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
US8283326B2 (en)	2006-10-27	2012-10-09	Boehringer Ingelheim International Gmbh	Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UY30730A1 (es) *	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101611032B (zh) *	2006-12-04	2012-07-18	詹森药业有限公司	作为抗糖尿病药的含噻吩基的吡喃葡糖基衍生物
ATE528300T1 (de)	2006-12-06	2011-10-15	Glaxosmithkline Llc	Bizyklische verbindungen und ihre verwendung als antidiabetika
KR101100072B1 (ko) *	2006-12-21	2011-12-29	고토부키 세이야쿠 가부시키가이샤	Ｃ-글리코시드 유도체의 제조방법 및 이의 합성 중간체
DE102007008420A1 (de)	2007-02-21	2008-08-28	Merck Patent Gmbh	Benzimidazolderivate
WO2008109591A1 (fr) *	2007-03-08	2008-09-12	Lexicon Pharmaceuticals, Inc.	Analogues de phlorizine utilisés comme inhibiteurs du co-transporteur 2 du sodium-glucose
AU2014201239B2 (en) *	2007-03-22	2016-03-10	Astrazeneca Ab	Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
TW200904454A (en) *	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) *	2007-03-22	2009-07-01	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
PE20090696A1 (es)	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2527360B1 (fr)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008279424B2 (en) *	2007-07-26	2013-06-13	Lexicon Pharmaceuticals, Inc.	Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
PE20090938A1 (es) *	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20090603A1 (es) *	2007-08-16	2009-06-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
BRPI0815405A2 (pt) *	2007-08-17	2015-02-03	Boehringer Ingelheim Int	Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
MX2010002027A (es) *	2007-08-23	2010-03-15	Theracos Inc	Derivados de bencilbenceno y metodos de uso.
MX2010002695A (es) *	2007-09-10	2010-04-01	Janssen Pharmaceutica Nv	Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
DE102007048716A1 (de)	2007-10-11	2009-04-23	Merck Patent Gmbh	Imidazo[1,2-a]pyrimidinderivate
JP5498392B2 (ja) *	2007-11-30	2014-05-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) *	2007-12-27	2015-03-04	阿斯利康公司	Sglt2 抑制剂的晶体结构及其制备方法
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
ES2541141T3 (es) *	2008-01-31	2015-07-16	Astellas Pharma Inc.	Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
CN101503399B (zh) *	2008-02-04	2012-06-27	白鹭医药技术（上海）有限公司	C-芳基葡萄糖苷sglt2抑制剂
UA105362C2 (en) *	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
DE102008017590A1 (de)	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
WO2009143010A1 (fr) *	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Procédé de traitement d'une hyponatrémie à l'aide d'un inhibiteur de sglt2 et composition le contenant
WO2009143021A1 (fr) *	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Procédé pour traiter et prévenir des calculs rénaux à l'aide d'un inhibiteur de sglt2 et composition le contenant
US8791077B2 (en) *	2008-05-22	2014-07-29	Astrazeneca Ab	Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
EP2810951B1 (fr)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
AU2009270936B2 (en) *	2008-07-15	2014-12-18	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
EP3241839B1 (fr)	2008-07-16	2019-09-04	Bausch Health Ireland Limited	Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UA119131C2 (uk) *	2008-08-15	2019-05-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Похідні пурину для застосування при лікуванні пов'язаних із fab захворювань
MX2011001855A (es) *	2008-08-22	2011-03-24	Theracos Inc	Procesos para la preparacion de inhibidores de sglt2.
MY155418A (en) *	2008-08-28	2015-10-15	Pfizer	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
JP5453431B2 (ja)	2008-09-08	2014-03-26	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
CA2736421A1 (fr)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Polytherapie pour le traitement du diabete et des etats pathologiques apparentes
EA201100502A1 (ru) *	2008-09-19	2011-10-31	Новартис Аг	Гликозидные производные и их применения
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
WO2010045656A2 (fr) *	2008-10-17	2010-04-22	Nectid, Inc.	Nouvelles formes posologiques d'inhibiteur sglt2
JP2012512848A (ja)	2008-12-23	2012-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	有機化合物の塩の形態
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
AP2011005795A0 (en)	2009-02-13	2011-08-31	Boehringer Ingelheim Int	SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia.
KR101921934B1 (ko) *	2009-02-13	2018-11-26	베링거 인겔하임 인터내셔날 게엠베하	글루코피라노실 디페닐메탄 유도체를 포함하는 약제학적 조성물, 이들의 약제학적 용량형, 이들의 제조방법 및 환자에서의 개선된 당 조절을 위한 이들의 용도
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BRPI1008560B1 (pt)	2009-02-13	2021-08-31	Boehringer Ingelheim International Gmbh	Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
SG173801A1 (en) *	2009-02-23	2011-09-29	Taisho Pharmaceutical Co Ltd	4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
EP2226076A1 (fr)	2009-02-25	2010-09-08	Henning Vollert	Support d'enregistrement thermosensible et procédé d'enregistrement
PE20120505A1 (es)	2009-03-31	2012-05-09	Boehringer Ingelheim Int	Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
JP2012528170A (ja) *	2009-05-27	2012-11-12	ブリストル−マイヤーズスクイブカンパニー	別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
KR101532412B1 (ko)	2009-07-10	2015-06-29	얀센 파마슈티카 엔.브이.	1-(β-Ｄ-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
AR077859A1 (es) *	2009-08-12	2011-09-28	Boehringer Ingelheim Int	Compuestos para el tratamiento de trastornos del snc
AU2010303123B2 (en) *	2009-09-30	2014-02-27	Boehringer Ingelheim International Gmbh	Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
JP5758900B2 (ja)	2009-09-30	2015-08-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
SI2488515T1 (sl) *	2009-10-14	2017-04-26	Janssen Pharmaceutica Nv	Postopek za pripravo spojin, ki so uporabne kot inhibitorji SGLT2
US8163704B2 (en) *	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
EA021983B1 (ru)	2009-11-02	2015-10-30	Пфайзер Инк.	Производные диоксабицикло[3.2.1]октан-2,3,4-триола
EP3315124B1 (fr) *	2009-11-13	2021-01-06	Astrazeneca AB	Formulations de comprimés bicouches
JP5784623B2 (ja)	2009-11-13	2015-09-24	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	速放性錠剤製剤
AU2010317842A1 (en)	2009-11-16	2012-07-12	Mellitech	[1,5]-diazocin derivatives
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011070592A2 (fr)	2009-12-09	2011-06-16	Panacea Biotec Ltd.	Nouveaux dérivés de sucres
CN102134226B (zh) *	2010-01-26	2013-06-12	天津药物研究院	一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (fr)	2010-03-03	2011-09-09	Sanofi	Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2552442A1 (fr)	2010-03-30	2013-02-06	Boehringer Ingelheim International GmbH	Composition pharmaceutique comprenant un inhibiteur sglt2 et un agoniste ppar-gamma, utilisations correspondantes
CA3070513C (fr)	2010-05-05	2023-01-03	Boehringer Ingelheim International Gmbh	Inhibiteur de dpp-4 a utiliser dans le traitement des transformations dela peau ou de la necrose
TWI599360B (zh)	2010-05-11	2017-09-21	健生藥品公司	醫藥調配物
JP5596799B2 (ja)	2010-05-11	2014-09-24	田辺三菱製薬株式会社	カナグリフロジン含有錠剤
WO2011153712A1 (fr)	2010-06-12	2011-12-15	Theracos, Inc.	Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
KR20130093012A (ko)	2010-06-24	2013-08-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AP2012006631A0 (en)	2010-08-12	2012-12-31	Boehringer Ingelheim Int	6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
WO2012025857A1 (fr)	2010-08-23	2012-03-01	Hetero Research Foundation	Dérivés de cycloalkyl méthoxybenzyl phényl pyrane en tant qu'inhibiteurs du cotransporteur de glucose sodium-dépendant (sglt2)
CN103370064A (zh)	2010-09-03	2013-10-23	百时美施贵宝公司	使用水溶性抗氧化剂的药物制剂
US8921328B2 (en)	2010-09-14	2014-12-30	Glycomimetics, Inc.	E-selectin antagonists
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (fr)	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
CN102453026A (zh)	2010-10-27	2012-05-16	上海艾力斯医药科技有限公司	C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
TWI631963B (zh) *	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CA2826391C (fr)	2011-02-01	2017-01-24	Bristol-Myers Squibb Company	Formulations pharmaceutiques comprenant un compose amine
US20130035281A1 (en) *	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en)	2011-02-15	2014-08-19	Boehringer Ingelheim International Gmbh	6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102643256B (zh)	2011-02-18	2014-12-24	上海璎黎科技有限公司	一种芳基糖苷类化合物及其制备方法和应用
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102167715B (zh) *	2011-03-07	2013-04-24	上海惠斯生物科技有限公司	一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
RS55056B1 (sr)	2011-04-13	2016-12-30	Janssen Pharmaceutica Nv	Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
KR101609859B1 (ko) *	2011-04-25	2016-04-07	베이징 프릴루드 팜. 에스씨아이. & 테크. 씨오., 엘티디.	소듐-의존적 포도당 운반 단백질의 억제제 및 이의 제조방법 및 용도
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
AP3308A (en) *	2011-05-26	2015-06-30	Tfchem	Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
EP2529742B1 (fr)	2011-06-03	2013-11-20	ratiopharm GmbH	Composition pharmaceutique comportant de la dapagliflozine et cyclodextrine
US9480755B2 (en) *	2011-06-03	2016-11-01	Ratiopharm Gmbh	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
BR112013031032A2 (pt)	2011-06-03	2016-11-29	Boehringer Ingelheim Int	inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
US9562029B2 (en)	2011-06-25	2017-02-07	Xuanzhu Pharma Co., Ltd.	C-glycoside derivatives
US20130035298A1 (en)	2011-07-08	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
DK2731947T3 (en)	2011-07-15	2019-04-23	Boehringer Ingelheim Int	SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9018249B2 (en)	2011-09-13	2015-04-28	Panacea Biotec Limited	SGLT inhibitors
CN103889429B (zh) *	2011-10-31	2016-10-19	台湾神隆股份有限公司	Sglt2抑制剂的结晶和非结晶形式
EP2597090A1 (fr)	2011-11-28	2013-05-29	Sandoz AG	Hydrate de dapagliflozine cristalline
PT2794626T (pt)	2011-12-22	2018-01-12	Glycomimetics Inc	Compostos de antagonistas de e-selectina
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013171166A1 (fr)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de sirs et/ou d'une sepsie
WO2013171167A1 (fr)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2013178064A1 (fr) *	2012-05-29	2013-12-05	广东东阳光药业有限公司	Dérivé glucopyranosyle, son procédé de préparation et son application pharmaceutique
EP3549587A1 (fr)	2012-06-30	2019-10-09	BioActive Food GmbH	Composition pour le traitement de pathologies hyperglycémiques
US9320727B2 (en) *	2012-08-30	2016-04-26	Taisho Pharmaceutical Co., Ltd	Combinations of SGLT 2 inhibitors and antihypertensive drugs
CA2891514C (fr)	2012-12-07	2020-08-25	Glycomimetics, Inc.	Composes, compositions et procedes utilisant des antagonistes d'e-selectine pour la mobilisation de cellules hematopoietiques
CN103910769B (zh)	2012-12-31	2018-10-02	上海璎黎药业有限公司	葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (fr)	2013-03-04	2016-05-18	BioActive Food GmbH	Composition pour le traitement de pathologies hyperglycémiques
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
EP2968375B1 (fr)	2013-03-14	2019-06-12	MSD International GmbH	Procédés de préparation d'inhibiteurs de sglt2
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
CA2905435A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions utiles pour le traitement de troubles gastro-intestinaux
CA2905438A1 (fr)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et leurs utilisations
DK2981269T3 (da)	2013-04-04	2023-10-23	Boehringer Ingelheim Vetmedica Gmbh	Behandling af stofskifteforstyrrelser hos hestedyr
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr)	2013-04-05	2019-03-08	Boehringer Ingelheim International Gmbh	Terapeutske uporabe empagliflozina
CA2812519A1 (fr)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
FI4000608T3 (fi)	2013-04-18	2026-01-21	Boehringer Ingelheim Int	Farmaseuttinen koostumus, menetelmä hoitamiseksi ja sen käyttöjä
WO2014178040A1 (fr)	2013-04-29	2014-11-06	Mapi Pharma Ltd.	Co-cristaux de dapagliflozine
SI3004138T1 (sl)	2013-06-05	2024-07-31	Bausch Health Ireland Limited	Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US20160214953A1 (en)	2013-09-23	2016-07-28	Sun Pharmaceutical Industries Limited	Process for the preparation of dapagliflozin
EP3049397A1 (fr) *	2013-09-27	2016-08-03	Sun Pharmaceutical Industries Ltd	Procédé de purification de dapagliflozin
WO2015043511A1 (fr)	2013-09-27	2015-04-02	Sunshine Lake Pharma Co., Ltd.	Dérivés de glucopyranosyl et leurs utilisations en médecine
WO2015051484A1 (fr)	2013-10-12	2015-04-16	Theracos, Inc.	Préparation de dérivés d'hydroxy-benzylbenzène
WO2015063726A1 (fr)	2013-10-31	2015-05-07	Ranbaxy Laboratories Limited	Procédé de préparation de 4-bromo-1-chloro-2-(4-éthoxybenzyl)benzène
MX376097B (es)	2013-12-17	2025-03-07	Boehringer Ingelheim Vetmedica Gmbh	Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos.
US9902751B2 (en)	2013-12-30	2018-02-27	Mylan Laboratories Limited	Process for the preparation of empagliflozin
CN104761522B (zh) *	2014-01-03	2017-02-15	山东轩竹医药科技有限公司	光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
US9315438B2 (en)	2014-01-03	2016-04-19	Xuanzhu Pharma Co., Ltd	Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CA2932674C (fr)	2014-01-23	2023-01-24	Boehringer Ingelheim Vetmedica Gmbh	Traitement de troubles metaboliques chez des animaux canins
CN103739581B (zh) *	2014-01-23	2016-11-23	中国药科大学	C-芳基葡萄糖苷sglt2抑制剂
CN104829572B (zh) *	2014-02-10	2019-01-04	江苏豪森药业集团有限公司	达格列净新晶型及其制备方法
IN2014MU00626A (fr) *	2014-02-21	2015-09-25	Cadila Healthcare Ltd
EP3110402A1 (fr)	2014-02-28	2017-01-04	Sun Pharmaceutical Industries Ltd	Compositions de dapagliflozin
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
EP3114115A4 (fr) *	2014-03-06	2017-08-23	MSN Laboratories Private Limited	Procédé pour la préparation de (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-éthoxyphényl)méthyl]phényl]-d-glucitol et de son solvate
FI3721882T3 (fi)	2014-04-01	2024-09-24	Boehringer Ingelheim Vetmedica Gmbh	Aineenvaihduntahäiriöiden hoito hevoseläimissä
CN105001213B (zh) *	2014-04-14	2020-08-28	上海迪诺医药科技有限公司	C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2944311A1 (fr)	2014-05-16	2015-11-18	BioActive Food GmbH	Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
EP3142661B1 (fr) *	2014-05-16	2021-10-06	Astrazeneca AB	Méthode de suppression de la sécrétion de glucagon d'un inhibiteur de sglt2
EP3229814A4 (fr)	2014-06-23	2018-07-11	Sun Pharmaceutical Industries Ltd	Co-cristal de dapagliflozin et d'acide citrique
JP2017528499A (ja)	2014-09-25	2017-09-28	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
EP4403230A3 (fr)	2014-09-25	2025-01-08	Boehringer Ingelheim Vetmedica GmbH	Traitement combiné d'inhibiteurs de sglt2 et d'agonistes de la dopamine pour la prévention de troubles métaboliques chez des équidés
CN104327027B (zh) *	2014-10-14	2017-04-05	中国药科大学	一类新型c‑芳基葡萄糖苷sglt2抑制剂
CN104478839A (zh) *	2014-11-24	2015-04-01	苏州乔纳森新材料科技有限公司	一种达格列净的合成方法
CN104496952B (zh) *	2014-11-28	2017-04-19	深圳翰宇药业股份有限公司	一种达格列净的合成方法
ES2754549T3 (es)	2014-12-03	2020-04-20	Glycomimetics Inc	Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
CN105753910A (zh) *	2014-12-16	2016-07-13	康普药业股份有限公司	一种卡格列净中间体的制备方法
CN104529970A (zh) *	2015-01-08	2015-04-22	江苏联环药业股份有限公司	制备达格列净的方法
CN104478966A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478959A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478957A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104530149A (zh) *	2015-01-14	2015-04-22	佛山市赛维斯医药科技有限公司	卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478968A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478965A (zh) *	2015-01-15	2015-04-01	佛山市赛维斯医药科技有限公司	一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
CN104497070A (zh) *	2015-01-15	2015-04-08	佛山市赛维斯医药科技有限公司	一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
CN104478963A (zh) *	2015-01-15	2015-04-01	佛山市赛维斯医药科技有限公司	一种含腈基苯s-葡萄糖苷结构的化合物及其用途
WO2016128995A1 (fr)	2015-02-09	2016-08-18	Indoco Remedies Limited	Procédé de préparation de composés inhibiteurs de sglt
EA201791982A1 (ru)	2015-03-09	2020-02-17	Интекрин Терапьютикс, Инк.	Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2016161995A1 (fr)	2015-04-08	2016-10-13	Zentiva, K.S.	Formes solides de dapagliflozine amorphe
WO2016178148A1 (fr) *	2015-05-05	2016-11-10	Glenmark Pharmaceuticals Limited	Procédé de préparation de dapagliflozine
CN106317068A (zh) *	2015-06-23	2017-01-11	中国科学院上海药物研究所	一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN104961715B (zh) *	2015-07-10	2017-08-22	浙江美诺华药物化学有限公司	一种达格列净的制备方法
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
ES2896101T3 (es)	2015-09-15	2022-02-23	Laurus Labs Ltd	Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
CZ2015729A3 (cs)	2015-10-13	2017-04-26	Zentiva, K.S.	Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN105218329B (zh) *	2015-10-15	2017-05-03	上海应用技术学院	一种列净类似物中间体及其制备方法
JP2018530592A (ja)	2015-10-15	2018-10-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	代謝性ミオパチーの治療に使用するためのｓｇｌｔ−２阻害剤
US9845303B2 (en)	2015-10-19	2017-12-19	Cadila Healthcare Limited	Process for the preparation of dapagliflozin
CN106892929B (zh) *	2015-12-17	2020-01-14	上海艾力斯医药科技有限公司	螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) *	2015-12-28	2016-06-22	南昌大学	一种抗糖尿病化合物及其制备方法和用途
DK3404033T3 (da) *	2016-01-04	2020-11-02	Jeil Pharmaceutical Co Ltd	C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette
WO2017118945A1 (fr)	2016-01-08	2017-07-13	Lupin Limited	Prémélange de dapagliflozine et son procédé de préparation
JP2019502727A (ja)	2016-01-22	2019-01-31	グリコミメティクス，インコーポレイテッド	Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
US9834533B2 (en) *	2016-02-19	2017-12-05	Scinopharm Taiwan, Ltd.	Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017151708A1 (fr)	2016-03-02	2017-09-08	Glycomimetics, Inc.	Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
MX2018011696A (es)	2016-03-31	2019-06-06	Lupin Ltd	Composición farmacéutica de dapagliflozina.
CN107304194A (zh) *	2016-04-20	2017-10-31	扬子江药业集团上海海尼药业有限公司	制备达格列净的方法
EP3466939B1 (fr) *	2016-05-24	2021-02-24	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	Nouvelle forme cristalline de la dapagliflozine, son procédé de préparation et son utilisation
WO2017203229A1 (fr)	2016-05-27	2017-11-30	Cipla Limited	Prémélanges de dapagliflozine
EP4233840A3 (fr)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinaisons de linagliptine et de metformine
WO2018002673A1 (fr)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
EP3497131B1 (fr)	2016-08-08	2022-03-09	GlycoMimetics, Inc.	Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
EP3497090B1 (fr) *	2016-08-09	2022-08-03	Laurus Labs Limited	Nouveaux procédés de préparation de dapagliflozine ou de ses solvates ou co-cristaux de celle-ci
WO2018029264A1 (fr)	2016-08-10	2018-02-15	Amneal Pharmaceuticals Company Gmbh	Procédé de préparation de dapagliflozine et de ses intermédiaires
US11072625B2 (en)	2016-10-07	2021-07-27	Glycomimetics, Inc.	Highly potent multimeric e-selectin antagonists
BR112019005930A2 (pt)	2016-10-19	2019-06-11	Boehringer Ingelheim Int	combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
KR20250097990A (ko)	2016-11-10	2025-06-30	베링거 인겔하임 인터내셔날 게엠베하	약제학적 조성물, 치료 방법 및 이의 용도
KR20180058510A (ko)	2016-11-24	2018-06-01	한미약품 주식회사	다파글리플로진 l-프롤린을 포함하는 약제학적 제제
CN108218928B (zh) *	2016-12-13	2020-06-30	华润双鹤药业股份有限公司	葡萄糖苷的二环衍生物及其制备方法和用途
WO2018142422A1 (fr) *	2017-02-02	2018-08-09	Indoco Remedies Limited	Procédé de préparation de dapagliflozine
CA3054605A1 (fr)	2017-03-15	2018-09-20	Glycomimetics, Inc.	Derives de galactopyranosyle-cyclohexyle utilises en tant qu'antagonistes d'e-selectine
WO2018167589A1 (fr)	2017-03-16	2018-09-20	Inventia Healthcare Private Limited	Composition pharmaceutique comprenant de la dapagliflozine
AU2018249822A1 (en)	2017-04-03	2019-10-31	Coherus Biosciences Inc.	PPArgamma agonist for treatment of progressive supranuclear palsy
US11198703B2 (en)	2017-05-09	2021-12-14	Piramal Enterprises Limited	Process for the preparation of SGLT2 inhibitors and intermediates thereof
AR112015A1 (es)	2017-06-09	2019-09-11	Novo Nordisk As	Composiciones sólidas para administración oral
KR101943382B1 (ko)	2017-09-19	2019-01-29	오토텔릭바이오 주식회사	Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
WO2019108750A1 (fr)	2017-11-30	2019-06-06	Glycomimetics, Inc.	Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
KR20260037123A (ko) *	2017-11-30	2026-03-17	이도르시아 파마슈티컬스 리미티드	엔도텔린 관련 질병의 치료를 위한 sglt-2 저해제와의 4-피리미딘설파미드 유도체의 병용
CN111566117A (zh)	2017-12-29	2020-08-21	糖模拟物有限公司	E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2019173229A1 (fr)	2018-03-05	2019-09-12	Glycomimetics, Inc.	Méthodes de traitement de la leucémie aiguë myéloïde et d'états pathologiques associés
US20210113561A1 (en)	2018-04-17	2021-04-22	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
KR102204439B1 (ko)	2018-05-14	2021-01-18	에이치케이이노엔 주식회사	Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
EP3810623A1 (fr)	2018-06-25	2021-04-28	Pharmathen S.A.	Nouveau procédé de préparation d'inhibiteurs de sglt-2
BR112021000139A2 (pt)	2018-07-19	2021-04-06	Astrazeneca Ab	Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2020039394A1 (fr)	2018-08-24	2020-02-27	Novartis Ag	Nouvelles combinaisons de médicaments
KR102131359B1 (ko)	2018-09-07	2020-07-07	오토텔릭바이오 주식회사	안정성이 향상된 의약 조성물
DK3873600T5 (da)	2018-10-29	2024-03-18	Boehringer Ingelheim Int	Pyridinylsulfonamidderivater, farmaceutiske sammensætninger og anvendelser deraf
US12213970B2 (en)	2018-10-29	2025-02-04	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109705075B (zh) *	2018-12-13	2022-12-23	苏中药业集团股份有限公司	一种达格列净的纯化方法
US11845771B2 (en)	2018-12-27	2023-12-19	Glycomimetics, Inc.	Heterobifunctional inhibitors of E-selectin and galectin-3
EP3771480A1 (fr)	2019-08-01	2021-02-03	Lexicon Pharmaceuticals, Inc.	Procédé continu de préparation de la forme cristalline ii de sotagliflozine
WO2021037400A1 (fr)	2019-08-30	2021-03-04	Astrazeneca Ab	Méthodes de traitement de l'insuffisance cardiaque à fraction d'éjection réduite avec la dapagliflozine
EP4064854A1 (fr)	2019-11-28	2022-10-05	Boehringer Ingelheim Vetmedica GmbH	Utilisation d'inhibiteurs de sglt-2 dans le séchage de mammifères non humains
JP7423800B2 (ja)	2020-02-17	2024-01-29	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用
UA128665C2 (uk)	2020-02-21	2024-09-18	Заклади Фармацеутичне Полфарма С.А.	Фармацевтична композиція, яка містить аморфний дапагліфлозин
EP4114365A1 (fr)	2020-03-05	2023-01-11	KRKA, d.d., Novo mesto	Composition pharmaceutique comprenant un inhibiteur du sglt2
CA3173808A1 (fr)	2020-03-06	2021-09-10	Vertex Pharmaceuticals Incorporated	Methodes de traitement de la glomerulosclerose segmentaire et focale dependante de l'apol -1
EP4138826A1 (fr)	2020-04-22	2023-03-01	Bayer Aktiengesellschaft	Combinaison de finérénone et d'un inhibiteur de sglt2 pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou rénales
US20230165856A1 (en)	2020-04-29	2023-06-01	Astrazeneca Ab	Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
EP4161912A1 (fr)	2020-06-05	2023-04-12	KRKA, d.d., Novo mesto	Préparation de dapagliflozine amorphe très pure
WO2021260617A1 (fr) *	2020-06-25	2021-12-30	Hikal Limited	Procédé amélioré de préparation de monohydrate de dapagliflozine-propanediol
CN115803028A (zh)	2020-07-10	2023-03-14	阿斯利康(瑞典)有限公司	用于治疗慢性肾病的齐泊腾坦和达格列净的组合
TW202220672A (zh)	2020-07-27	2022-06-01	瑞典商阿斯特捷利康公司	用達格列淨治療慢性腎臟病之方法
AU2021202643B2 (en)	2020-07-27	2023-02-02	Astrazeneca Ab	Methods of treating chronic kidney disease with dapagliflozin
WO2022051316A1 (fr)	2020-09-03	2022-03-10	Coherus Biosciences, Inc.	Combinaisons à dose fixe de chs-131 et d'un inhibiteur de sglt-2
EP4206212A4 (fr)	2020-09-30	2024-05-22	Beijing Creatron Institute of Pharmaceutical Research Co., Ltd.	Cocristal d'inhibiteur de sglt-2 et de sarcosine, procédé pour sa préparation et utilisation correspondante
TR202019589A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
TR202019592A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Amorf dapagliflozinin katı farmasötik formülasyonları
WO2022119543A1 (fr)	2020-12-03	2022-06-09	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
TR202019590A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
EP4315350A1 (fr)	2021-04-01	2024-02-07	AstraZeneca UK Limited	Systèmes et méthodes de gestion de prédiabète à l'aide d'une composition pharmaceutique d'inhibiteur de cotransport 2 de sodium-glucose à base de gliflozine
EP4079296A1 (fr)	2021-04-21	2022-10-26	Sanovel Ilac Sanayi Ve Ticaret A.S.	Formulation de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
US20240269105A1 (en)	2021-07-28	2024-08-15	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
MX2024001184A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
CN117715639A (zh)	2021-07-28	2024-03-15	勃林格殷格翰动物保健有限公司	Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
CN113773194B (zh)	2021-08-16	2023-05-02	浙江奥翔药业股份有限公司	作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
AU2022425078A1 (en)	2021-12-30	2024-08-08	Newamsterdam Pharma B.V.	Obicetrapib and sglt2 inhibitor combination
EP4212150A1 (fr)	2022-01-13	2023-07-19	Sanovel Ilac Sanayi Ve Ticaret A.S.	Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
US20250108065A1 (en)	2022-01-26	2025-04-03	Astrazeneca Ab	Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
WO2023227492A1 (fr)	2022-05-25	2023-11-30	Boehringer Ingelheim Vetmedica Gmbh	Compositions pharmaceutiques aqueuses comprenant des inhibiteurs de sglt-2
EP4536207A1 (fr)	2022-06-07	2025-04-16	Astrazeneca AB	Combinaisons de modulateurs de rxfp1 et d'inhibiteurs de sglt2
KR102490653B1 (ko) *	2022-08-03	2023-01-20	진양제약주식회사	다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
KR20240028315A (ko)	2022-08-24	2024-03-05	주식회사 제뉴원사이언스	다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
CN120641101A (zh)	2023-02-08	2025-09-12	阿斯利康(瑞典)有限公司	用于治疗高蛋白尿慢性肾病的齐泊腾坦和达格列净的组合
EP4427742A1 (fr)	2023-03-06	2024-09-11	Galenicum Health S.L.U.	Compositions pharmaceutiques comprenant de la dapagliflozine et de la metformine
EP4431088A1 (fr)	2023-03-06	2024-09-18	Galenicum Health S.L.U.	Compositions pharmaceutiques comprenant de la dapagliflozine et de la metformine
JP2026508912A (ja)	2023-03-06	2026-03-13	ベーリンガーインゲルハイムフェトメディカゲーエムベーハー	液体医薬組成物、特に１種又は複数のｓｇｌｔ－２阻害剤を含む液体医薬組成物の送達のためのシステム
WO2024210557A1 (fr)	2023-04-05	2024-10-10	한미약품 주식회사	Formulation combinée comprenant du sacubitril-valsartan et un inhibiteur de sglt-2 ayant une stabilité et un taux de dissolution améliorés
WO2024226537A1 (fr)	2023-04-24	2024-10-31	Newamsterdam Pharma B.V.	Combinaison d'inhibiteur de sglt2 et d'obicetrapib amorphe
CN121175053A (zh)	2023-05-24	2025-12-19	勃林格殷格翰动物保健有限公司	包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
TW202508593A (zh)	2023-05-24	2025-03-01	德商百靈佳殷格翰維美迪加股份有限公司	包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
EP4487910A1 (fr) *	2023-07-06	2025-01-08	Zaklady Farmaceutyczne Polpharma S.A.	Procédé de préparation de dapagliflozine
WO2025069009A1 (fr)	2023-09-29	2025-04-03	Graviton Bioscience Bv	Inhibiteurs de rock2 dans le traitement de l'obésité
EP4556001A1 (fr)	2023-11-14	2025-05-21	Sanovel Ilac Sanayi ve Ticaret A.S.	Composition de comprimé bicouche comprenant de la dapagliflozine et de la metformine
WO2025125513A1 (fr)	2023-12-15	2025-06-19	AstraZeneca Ireland Limited	Inhibiteurs de sglt2 et baxdrostat pour le traitement d'une maladie rénale chronique et de l'hypertension
WO2025133907A1 (fr)	2023-12-18	2025-06-26	Astrazeneca Ab	Combinaison de zibotentan et de dapagliflozine pour le traitement de l'angine microvasculaire
WO2025160910A1 (fr) *	2024-02-01	2025-08-07	New Wish Biotechnology Wuxi Co., Ltd.	Composé indazole et composition pharmaceutique, son procédé de préparation et son utilisation
WO2025163559A1 (fr)	2024-02-01	2025-08-07	Astrazeneca Ab	Combinaison de zibotentan et de dapagliflozine destinée à être utilisée pour le traitement de l'hypertension
CN118908926A (zh) *	2024-07-24	2024-11-08	安徽海康药业股份有限公司	一种达格列净的合成方法
WO2026078068A1 (fr)	2024-10-09	2026-04-16	Astrazeneca Ab	Combinaison de zibotentan et de dapagliflozine pour le traitement d'une maladie rénale chronique et d'une fibrose hépatique

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH03133746A (ja) *	1989-10-19	1991-06-06	Taiyo Kagaku Kogyo Kk	自立袋およびその製造方法
CA2102591C (fr)	1992-11-12	2000-12-26	Kenji Tsujihara	Agent hypoglycemiant
WO1994011030A1 (fr) *	1992-11-13	1994-05-26	The Ohio State University Research Foundation	Analogues arylamide de n-(4-hydroxyphenyl)retinamide-o-glucuronide
US5444050A (en) *	1994-04-29	1995-08-22	Texas Biotechnology Corporation	Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
US5830873A (en)	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja)	1994-05-11	1998-10-27	田辺製薬株式会社	血糖降下剤
JP3006513B2 (ja)	1995-11-07	2000-02-07	田辺製薬株式会社	医薬組成物
JP3059088B2 (ja)	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
JP3034192B2 (ja)	1995-11-07	2000-04-17	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
AU719726B2 (en)	1996-12-26	2000-05-18	Tanabe Seiyaku Co., Ltd.	Propiophenone derivatives and process for preparing the same
AU6024998A (en)	1997-01-15	1998-08-07	Glycomed Incorporated	Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja)	1997-03-03	1998-09-14	Dainippon Ink & Chem Inc	７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
ATE298740T1 (de) *	1997-04-04	2005-07-15	Mitsubishi Pharma Corp	2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JP3451000B2 (ja)	1997-10-20	2003-09-29	新日本製鐵株式会社	方向性珪素鋼板の絶縁皮膜形成方法
DE19806803A1 (de) *	1998-02-18	1999-11-25	Hermann Koepsell	Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
GB9811427D0 (en) *	1998-05-29	1998-07-22	Zeneca Ltd	Chemical compounds
US6486299B1 (en)	1998-09-28	2002-11-26	Curagen Corporation	Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
AUPP823099A0 (en) *	1999-01-18	1999-02-11	Alchemia Pty Ltd	Protecting groups for carbohydrate synthesis
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) *	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6683056B2 (en) *	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) *	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
WO2002083066A2 (fr) *	2001-04-11	2002-10-24	Bristol-Myers Squibb Company	Complexes acides amines de glugocides c-aryle pour le traitement du diabete et procede correspondant

2002
- 2002-05-20 US US10/151,436 patent/US6515117B2/en not_active Expired - Lifetime
2003
- 2003-05-14 TW TW092113121A patent/TWI310770B/zh active
- 2003-05-15 CN CNA2007101089864A patent/CN101092409A/zh active Pending
- 2003-05-15 KR KR1020047018685A patent/KR101021752B1/ko not_active Ceased
- 2003-05-15 ES ES03736643T patent/ES2280759T3/es not_active Expired - Lifetime
- 2003-05-15 DK DK03736643T patent/DK1506211T3/da active
- 2003-05-15 MX MXPA04011371 patent/MX249731B/es active IP Right Grant
- 2003-05-15 UA UA20041210415A patent/UA77306C2/uk unknown
- 2003-05-15 JP JP2004507493A patent/JP5090621B2/ja not_active Expired - Lifetime
- 2003-05-15 AT AT03736643T patent/ATE353334T1/de active
- 2003-05-15 PL PL373369A patent/PL210304B1/pl unknown
- 2003-05-15 CN CN2009101586866A patent/CN101628905B/zh not_active Expired - Lifetime
- 2003-05-15 GE GEAP8537A patent/GEP20084403B/en unknown
- 2003-05-15 RS YUP-992/04A patent/RS51469B/sr unknown
- 2003-05-15 WO PCT/US2003/015591 patent/WO2003099836A1/fr not_active Ceased
- 2003-05-15 ME MEP-2008-130A patent/ME00091B/fr unknown
- 2003-05-15 RU RU2004137489/04A patent/RU2337916C2/ru not_active IP Right Cessation
- 2003-05-15 ME MEP-130/08A patent/MEP13008A/xx unknown
- 2003-05-15 DE DE60311649T patent/DE60311649T2/de not_active Expired - Lifetime
- 2003-05-15 NZ NZ536605A patent/NZ536605A/en not_active IP Right Cessation
- 2003-05-15 SI SI200330776T patent/SI1506211T1/sl unknown
- 2003-05-15 CN CN201410345395.9A patent/CN104230866A/zh active Pending
- 2003-05-15 CA CA2486539A patent/CA2486539C/fr not_active Expired - Lifetime
- 2003-05-15 CN CN201210054766.9A patent/CN102627676B/zh not_active Expired - Lifetime
- 2003-05-15 BR BR122017015091A patent/BR122017015091B8/pt active IP Right Grant
- 2003-05-15 AU AU2003237886A patent/AU2003237886B2/en active Active
- 2003-05-15 PT PT03736643T patent/PT1506211E/pt unknown
- 2003-05-15 BR BRPI0311323A patent/BRPI0311323B8/pt active IP Right Grant
- 2003-05-15 HR HR20041084A patent/HRP20041084B1/xx not_active IP Right Cessation
- 2003-05-15 CN CNB038113538A patent/CN100534997C/zh not_active Expired - Lifetime
- 2003-05-15 EP EP03736643A patent/EP1506211B1/fr not_active Expired - Lifetime
- 2003-05-16 AR ARP030101713A patent/AR040032A1/es active IP Right Grant
- 2003-05-16 MY MYPI20031803A patent/MY142499A/en unknown
- 2003-05-20 PE PE2003000491A patent/PE20040760A1/es active IP Right Grant
2004
- 2004-11-09 IL IL16511904A patent/IL165119A0/xx active Protection Beyond IP Right Term
- 2004-11-11 NO NO20044915A patent/NO329107B1/no not_active IP Right Cessation
- 2004-11-16 IS IS7529A patent/IS7529A/is unknown
- 2004-11-16 IN IN3573DE2004 patent/IN2004DE03573A/en unknown
- 2004-11-18 ZA ZA200409295A patent/ZA200409295B/xx unknown
2007
- 2007-05-03 CY CY20071100584T patent/CY1106465T1/el unknown
2008
- 2008-06-06 RU RU2008122558A patent/RU2489151C3/ru active Protection Beyond IP Right Term
2009
- 2009-08-18 JP JP2009189324A patent/JP5340077B2/ja not_active Expired - Lifetime
2012
- 2012-07-19 JP JP2012160579A patent/JP5584738B2/ja not_active Expired - Lifetime
2013
- 2013-04-03 LT LTPA2013008C patent/LTC1506211I2/lt unknown
- 2013-04-04 FR FR13C0022C patent/FR13C0022I2/fr active Active
- 2013-04-08 RU RU2013115635A patent/RU2643764C9/ru active IP Right Revival
- 2013-04-09 BE BE2013C025C patent/BE2013C025I2/fr unknown
- 2013-04-10 CY CY2013013C patent/CY2013013I2/el unknown
- 2013-04-12 NO NO2013007C patent/NO2013007I1/no unknown
- 2013-04-17 LU LU92182C patent/LU92182I2/fr unknown
- 2013-08-02 JP JP2013161572A patent/JP5604568B2/ja not_active Expired - Lifetime
2014
- 2014-07-08 FR FR14C0054C patent/FR14C0054I1/fr active Active
- 2014-07-09 NO NO2014017C patent/NO2014017I1/no unknown
- 2014-07-09 BE BE2014C041C patent/BE2014C041I2/fr unknown
- 2014-07-10 LU LU92496C patent/LU92496I2/fr unknown
- 2014-07-11 CY CY2014025C patent/CY2014025I2/el unknown
2015
- 2015-06-19 HK HK15105854.7A patent/HK1205120A1/xx unknown
2017
- 2017-09-07 RU RU2017131447A patent/RU2017131447A/ru unknown
2022
- 2022-10-03 NO NO2022041C patent/NO2022041I1/no unknown

Also Published As

Publication number	Publication date
LU92182I2 (fr)	2013-06-17
MEP13008A (en)	2010-06-10
LTC1506211I2 (lt)	2023-02-10
FR13C0022I2 (fr)	2014-03-07
JP2009275050A (ja)	2009-11-26
ES2280759T3 (es)	2007-09-16
CN102627676B (zh)	2014-08-20
CY2013013I1 (el)	2015-11-04
IL165119A0 (en)	2005-12-18
NO2013007I1 (no)	2013-04-29
KR101021752B1 (ko)	2011-03-15
MXPA04011371A (es)	2005-02-14
FR14C0054I1 (fr)	2014-08-08
FR13C0022I1 (fr)	2014-02-03
MX249731B (es)	2007-10-01
RU2017131447A (ru)	2019-03-07
RU2337916C2 (ru)	2008-11-10
NO2014017I1 (no)	2014-07-09
RU2489151C2 (ru)	2013-08-10
IN2004DE03573A (fr)	2005-04-01
PL373369A1 (en)	2005-08-22
EP1506211A1 (fr)	2005-02-16
PL210304B1 (pl)	2011-12-30
MY142499A (en)	2010-11-30
UA77306C2 (uk)	2006-11-15
AU2003237886A1 (en)	2003-12-12
BR0311323A (pt)	2005-03-15
RU2004137489A (ru)	2005-06-27
AU2003237886B2 (en)	2009-02-05
DK1506211T3 (da)	2007-04-10
CN104230866A (zh)	2014-12-24
HRP20041084A2 (en)	2005-06-30
IS7529A (is)	2004-11-16
PE20040760A1 (es)	2004-11-20
US20020137903A1 (en)	2002-09-26
BR122017015091B1 (pt)	2018-05-15
ZA200409295B (en)	2006-02-22
DE60311649T2 (de)	2007-11-22
RU2008122558A (ru)	2009-12-20
BE2014C041I2 (fr)	2022-08-09
NO20044915L (no)	2004-12-16
CN100534997C (zh)	2009-09-02
RU2013115635A (ru)	2014-10-20
CN1653075A (zh)	2005-08-10
HRP20041084B1 (hr)	2008-06-30
RS99204A (sr)	2006-12-15
ATE353334T1 (de)	2007-02-15
KR20050004161A (ko)	2005-01-12
RU2746132C1 (ru)	2021-04-07
RU2643764C2 (ru)	2018-02-05
DE60311649D1 (de)	2007-03-22
CN102627676A (zh)	2012-08-08
GEP20084403B (en)	2008-06-25
CN101628905A (zh)	2010-01-20
ME00091B (fr)	2010-10-10
CN101628905B (zh)	2012-03-21
RS51469B (sr)	2011-04-30
CY2014025I1 (el)	2015-11-04
CY2014025I2 (el)	2015-11-04
TWI310770B (en)	2009-06-11
RU2489151C3 (ru)	2019-11-28
RU2746132C3 (ru)	2021-08-02
BRPI0311323B1 (pt)	2017-09-26
CY1106465T1 (el)	2012-01-25
NO329107B1 (no)	2010-08-23
NZ536605A (en)	2007-05-31
BE2013C025I2 (fr)	2022-09-29
JP5340077B2 (ja)	2013-11-13
EP1506211A4 (fr)	2005-08-17
JP5604568B2 (ja)	2014-10-08
CN101092409A (zh)	2007-12-26
BR122017015091B8 (pt)	2021-07-27
AR040032A1 (es)	2005-03-09
BRPI0311323B8 (pt)	2021-05-25
CA2486539C (fr)	2012-03-13
HK1205120A1 (en)	2015-12-11
SI1506211T1 (sl)	2007-10-31
LU92496I2 (fr)	2014-09-10
NO2013007I2 (no)	2013-04-12
PT1506211E (pt)	2007-04-30
RU2017131447A3 (fr)	2021-01-14
LTPA2013008I1 (lt)	2013-05-27
HK1068214A1 (en)	2005-04-22
RU2643764C9 (ru)	2021-12-15
LU92182I9 (fr)	2019-01-04
TW200404813A (en)	2004-04-01
CY2013013I2 (el)	2015-11-04
JP2005531588A (ja)	2005-10-20
JP5584738B2 (ja)	2014-09-03
EP1506211B1 (fr)	2007-02-07
WO2003099836A1 (fr)	2003-12-04
US6515117B2 (en)	2003-02-04
JP2012207037A (ja)	2012-10-25
NO2022041I1 (no)	2022-10-03
CA2486539A1 (fr)	2003-12-04
JP2014028807A (ja)	2014-02-13

Legal Events

Date	Code	Title	Description
2006-03-29	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060328
2009-04-22	A871	Explanation of circumstances concerning accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20090421
2009-05-14	A975	Report on accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090511
2009-05-20	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519
2009-08-19	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090818
2009-09-18	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090917
2009-11-05	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091104
2010-03-03	C60	Trial request (containing other claim documents, opposition documents)	Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20100301
2012-07-04	C22	Notice of designation (change) of administrative judge	Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20120703
2012-07-05	C302	Record of communication	Free format text: JAPANESE INTERMEDIATE CODE: C302 Effective date: 20120704
2012-07-11	C13	Notice of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20120710
2012-07-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120713
2012-08-22	C03	Trial/appeal decision taken	Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20120821
2012-08-22	C30A	Notification sent	Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20120821
2012-08-23	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-09-20	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120913
2012-09-21	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150921 Year of fee payment: 3
2012-09-21	R150	Certificate of patent or registration of utility model	Ref document number: 5090621 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2014-05-02	S111	Request for change of ownership or part of ownership	Free format text: JAPANESE INTERMEDIATE CODE: R313113
2014-05-14	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2015-07-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-07-05	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-07-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-09-06	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2018-07-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-02-26	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2020-06-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-06-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-05-11	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2022-08-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-04-26	R153	Grant of patent term extension	Free format text: JAPANESE INTERMEDIATE CODE: R153
2023-08-31	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-09-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250